ReviewCurrent opinion in nephrology and hypertension2013
New targets for treatment of diabetic nephropathy: what we have learned from animal models.
Review in Current opinion in nephrology and hypertension, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Optimizing diabetic kidney disease animal models: Insights from a meta-analytic approach.Animal models and experimental medicine · 2023Pooled it
- Protective effect of paeoniflorin in diabetic nephropathy: A preclinical systematic review revealing the mechanism of action.PloS one · 2023Pooled it
- Article
- Review
- Mitochondrial ATP synthase as a direct molecular target of chromium(III) to ameliorate hyperglycaemia stress.Nature communications · 2023Article
- Article
- Kidney microRNA Expression Pattern in Type 2 Diabetic Nephropathy in BTBR Ob/Ob Mice.Frontiers in pharmacology · 2022Article
- Studying Kidney Diseases Using Organoid Models.Frontiers in cell and developmental biology · 2022Review
- Reversal of hypertriglyceridemia in diabetic BTBR ob/ob mice does not prevent nephropathy.Laboratory investigation; a journal of technical methods and pathology · 2021Article
- Roles of mTOR in Diabetic Kidney Disease.Antioxidants (Basel, Switzerland) · 2021Article
- VEGFR2 Blockade Improves Renal Damage in an Experimental Model of Type 2 Diabetic Nephropathy.Journal of clinical medicine · 2020Article
- Renal lesions in leptin receptor-deficient medaka (Journal of toxicologic pathology · 2019Article
- Epigenetics and epigenomics in diabetic kidney disease and metabolic memory.Nature reviews. Nephrology · 2019Review
- Mitochondrial uncoupling has no effect on microvascular complications in type 2 diabetes.Scientific reports · 2019Article
- Conserved Transcriptional Signatures in Human and Murine Diabetic Peripheral Neuropathy.Scientific reports · 2018Article
- Modelling diabetic nephropathy in mice.Nature reviews. Nephrology · 2018Review
- Podocyte-specific JAK2 overexpression worsens diabetic kidney disease in mice.Kidney international · 2017Article
- Advanced glycation end products induce the apoptosis of and inflammation in mouse podocytes through CXCL9-mediated JAK2/STAT3 pathway activation.International journal of molecular medicine · 2017Article
- Article
- Omics databases on kidney disease: where they can be found and how to benefit from them.Clinical kidney journal · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewThere has been an advance in our understanding of the mechanisms of diabetic nephropathy over the past few years and much of that has occurred because of studies in animal models of diabetic nephropathy. RECENT
findingsStudies in animal models of diabetic nephropathy, especially in mice, have underlined the multifactorial nature of the pathogenesis of the disease process and the recognition that these models only partly replicate the changes found in human disease. Despite these limitations, recent animal model studies have identified a number of new, specific molecular abnormalities that point to pathways and specific molecules as potential targets for preventive or therapeutic intervention. These specific targets include the diabetic nephropathy related decreases in endothelial nitric oxide synthase activity and renal dopamine production and the increases in Nrf-2, JAK/STAT, and mammalian target of rapamycin complex 1 signaling. These and other altered signaling pathways are described in this review. We emphasize the use of a unique investigative resource, Nephromine, to utilize a library of mRNA expression data obtained from the kidney biopsies of humans with diabetic nephropathy, to compare and validate findings in mouse models with human disease. SUMMARY: Several new pathways have been implicated in the progression of diabetic nephropathy through studies of animal models. Some of these appear to be altered in human diabetic nephropathy and may be targets for therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.